


Post-Event
Report

BIOMARKERS

SERIES UK 2020

PLUS 2021 Event Information

Statistics - Testimonials - Your Feedback - Photos - Resources



WELCOME TO THE BIOMARKERS SERIES UK 2020 POST-EVENT REPORT!

I'd like to start this introduction by thanking all attendees, partners and supporters of our 2020 event - this year's congress was our biggest biomarkers forum yet and we've received a range of hugely positive messages & feedback since the event - it's great to know the environment continues to drive such valuable networking and knowledge sharing.

This year's event kicked off in slightly different fashion, with the addition of a day dedicated to deep-dive morning workshops, covering biomarkers in Neuroscience, Oncology and Cardiovascular research. This was followed by a highly popular end-user workshop from our lead sponsor Covance, who led the audience through an informative session covering design and implementation of a Biomarker plan in drug development.

Following this open day of workshops was a very busy two days of presentation, discussion and networking, this year featuring over 70 speakers, 50 sponsors and almost 400 selected attendees. Topics included ranged from Biomarkers In Drug Discovery & Development, Biomarkers for Detection, Monitoring & Diagnosis, Biomarkers for Clinical & Pre-Clinical Development and New Biomarker Technologies & Data.

Alongside our main Biomarkers programme, this year also saw the launch of a dedicated Genomic Markers programme, providing insights into the best strategies to

integrate these technologies into the biomarker workflow and enable precision medicine. This popular programme will be with us again in 2021, supported by a new range of deep-dive workshops to open the event, and a new programme covering Digital Biomarkers, to be held the day after the main programme finish.

The continued expansion of our programme reflects the growing importance of Biomarkers across the discovery/development pipeline and we're pleased to continue to bring you this leading platform for new research, product launches and relationship building.





Please read on for some more insight and feedback from our 2020 event and a early peek of our plans for the 2021 Series.

- Hayley Watson,
Portfolio and Client Engagement Director



WHO DID YOU MEET AT MANCHESTER CENTRAL?

A BREAKDOWN OF THE BIOMARKERS SERIES ATTENDEE PROFILE:



I enjoyed the overall size of the event & the possibility to have 1-2-1 meetings during breaks. The gala diner was also organised in a nice venue

- Product Manager,
Charles River

Nice size, good presentations, comprehensive, not too vast or short. Nice structure and clear focus areas. Networking arrangements were super good! Updates and information before and throughout the meeting were well-managed.

- Head of Biomarkers and Molecular Imaging, CNS Discovery,
Charles River

I always find this event very focused, the attendees are always happy to network and chat, and are ready for a conversation. The content was also very relevant.

- Account Manager,
Meso Scale Discovery

There was a very close management of the event by the support team who were on the floor throughout the meeting.

The atmosphere was very cooperative and freindly, both exhibitor-to-exhibitor and between delegates and exhibitors. The location, floorplan, size of event, event management, demeanour of Oxford Global staff, helpfulness of the catering staff had a very complimentary mix.

- Senior Director Business Development,
Cerba Research

Good venue & good audiovisual! Good conference size. Enough time to mix the meetings with presentations, which had an interesting mix of speakers. The Conference dinner at Old Trafford stadium was a really good venue, food and wine also. We had a great table of guests with a rich tapestry of backgrounds and experience.

- Co-Founder, CEO and Director,
DESTINA Genomics Ltd

Extremely well organised, lots of networking opportunities, excellent speakers, relevant topics, great discussions

- Senior Analytical Development Scientist,
Adaptimmune

The App was extremely useful for organizing myself during the event and for recording notes. The amount and quality of service provided all brought together in one space was very useful and the free barista coffee was a lovely bonus.

- Research Scientist,
Fonterra

I liked the balance of talks and breaks. It gave ample time for networking with service providers. Talks were very targeted towards translational medicine and were very relevant. I came away with some really good ideas of technologies we could be using. There was also a good balance between formal talks and panel discussions. I liked that you had a choice as to which talk you attended as well, finding the rooms was easy and the layout was very good. The food was also good and stands were well organised.

- Scientist II,
PsiOxus Therapeutics

Plenty of time for networking, great talks, excellent panel sessions and delicious food. The size of the event was great.

- Business Development and Alliance Manager,
iOnctura

YOU SPOKE, WE LISTENED:

Location & Venue



We will once again host the congress in the wonderful city of Manchester.

Year on year you tell us how much you like the Manchester Central Convention Centre. Don't worry - it has been booked!



You liked the venue and parallel sessions but you found it challenging to navigate to the right conference room when changing from one track to another.

We will be improving our signage and venue maps in 2021 to aid easier movement between talks.

Programme Content



Your feedback showed that our 2020 programme was covering the most important or pertinent areas of research, but there were some exciting new developments we should consider covering in 2021.

Based on this feedback, our 2021 Series will include a dedicated programme for Digital Biomarkers, we'll continue to drill down into the range of other research topics that matter most to you.



Variety of Delegates



You told us you liked to see the continuous growth of the event and quality of networking opportunities.

The team will continue to attract biomarker specialists from pharma & academia. For 2021, you will see a 15% increase in attendees.

Networking



Your feedback again highlighted the popularity & value of our networking sessions and functions.

We will continue to improve our functions and networking experience in 2021, with opportunities to engage in 1-2-1 discussions and several dedicated networking functions planned.



FORTHCOMING EVENTS

BIOMARKERS SERIES UK 2021

16TH ANNUAL BIOMARKERS CONGRESS
2ND ANNUAL GENOMIC MARKERS
+ DIGITAL BIOMARKERS & PATHOLOGY CONGRESS

MANCHESTER CENTRAL, MANCHESTER, UK
08 - 11 FEBRUARY 2021

For exhibition or sponsorship enquiries e-mail:
sponsorship@oxfordglobal.co.uk
For speaker opportunities e-mail Cerlin Roberts:
c.roberts@oxfordglobal.co.uk
For delegate attendance enquiries e-mail:
marketing@oxfordglobal.co.uk

5TH ANNUAL BIOMARKERS & PRECISION MEDICINE USA CONGRESS

If you are looking for a US-based Biomarkers event, look no further than our **5th Annual Biomarkers & Precision Medicine USA Congress**, taking place 15 - 16 October 2020 in San Diego, USA. More details can be found at:

www.oxfordglobal.co.uk/biomarkers-series-us/



You don't need to wait until future events to get involved!

Our LinkedIn and Twitter groups are an excellent way of keeping up to date on the industry and with your peers.

Follow @bmd_congress on **Twitter** and join the Congress conversation with #BIOMUK20

Connect and network with industry and academic peers through our **LinkedIn** group.

Visit our **Content HUB** to gain access to our complimentary resources, including Webinar Recordings, Q&A Sessions, Video, Market Surveys, and much more!

>> Follow @bmd_congress

>> Join our LinkedIn group

>> Visit the Content HUB

Biomarker Identification & Development

Heidi Kingdon Jones, IRBM



The availability of **biomarkers can greatly facilitate** the interpretation of clinical trial results, but the use of poorly validated assays to detect them has resulted in a profound lack of useful biomarkers. The biomarker pipeline was recently described as **"plagued by problems"** and "too prone to failures". This could be due to the **lack of a robust biological connection** between the molecular marker and the disease-specific molecular dysfunction, or due to the **absence of a rigorous clinical validation**.

At IRBM we develop and validate biomarker assays **according to FDA/EMA guidelines** in order to minimize the technical variability **and ensure maximal reproducibility**. We employ **different technologies** for detection including:

- **Immunoassays** for protein and biologics detection (including anti-drug antibodies)
- **Mass spectrometry** for high sensitive metabolite detection
- **NMR** for metabolite profiling as a biomarker technique

One of IRBM's strengths is the development and validation of assays for the **detection of low-abundance protein** biomarkers. We have developed immunoassays by using ultrasensitive platforms like SMC (formerly Singulex, now SMCxPRO) and MesoScale Discovery. In 2020, we have advanced our platform in order to run several biomarker assays to GCP/GLP compliance. This includes:

- Production, qualification and handling of in-house produced reagents (e.g. standard proteins and derivatized antibodies)
- Fully traceability of samples and data analysis
- SOP regulated environment

We carry out the following tests according to validation guidelines, which are then provided in the form of a **validation report**:

- Performance of the standard curve
- Accuracy and precision
- Stability
- Linearity
- Parallelism
- Spike recovery
- Selectivity and specificity
- Reproducibility

The generation and validation of a **biomarker assay** early on during the development of a pharmaceutical product has proven to be **instrumental in the reduction of the attrition rate**. Thus, at IRBM, we understand the critical importance of **developing robust biomarkers that provide meaningful readouts**.

At the recent Oxford Global conference, Biomarkers Series UK, IRBM's Manuel Daldin presented on the development and validation of an assay to detect mutant huntingtin protein for the assessment of pharmacodynamic effects in human and rodent samples.

For further information on IRBM's Biomarker assays and capabilities please contact Bd@irbm.com



> The slides are available to read here on the IRBM website



THANK YOU TO OUR SPEAKERS AND SPONSORS

PLATINUM

COVANCE
SOLUTIONS MADE REAL®

GOLD

charles river PRA Health Sciences
 PELAGO BIOSCIENCE MSD®
 Personalis® MERCK

SILVER

MACS Miltenyi Biotec ALMAC LGC
 fios GENOMICS CANOPY BIOSENCES celerion
 biotechne® intertek Total Quality Assured. BioAgilytix
 nanoString myriad | RBM

BRONZE

Aquila BioMedical FLUIDIGM HEMATOGENIX HistologiX HTG indica labs QUANTITATIVE PATHOLOGY proteome sciences Quanterix The Science of Precision Health ULTIVUE Volition

NETWORK AND PROGRAMME SPONSORS

ARC REGULATORY AFFINITY BIOMARKER LABS SensID Luminex complexity simplified. Ziath BioLizard RANDOX BIOSCIENCES Cerba Research Your precision medicine partner epistem®
 IMMUNOLOGIX LABORATORIES CAPRION NEO GENOMICS IRBM 10th Anniversary ALDERLEY PARK Tissue Solutions PRO PATH ANGLE BREATH Biopsy Fluidic Analytics
 eurofins | DISCOVERY biogazelle DEFINIENS the tissue phenomics company METABOLON® KeenEye PPD® GYROS PROTEIN Technologies

Thank you once more to all who made the Biomarkers Series 2020 a success: to all attendees, speakers who presented at the event, and our sponsors above.
 We hope to see you again next year!



THANK YOU FOR COMING